Meet the MedCity Media Team

And take 2 minutes to help us make better for you.

Every year, we ask you to tell us a little about yourself (anonymously) to help us create better, more relevant content and features for you. We consider every response and very much appreciate you taking the time to assist us.

Please click the button above to open a simple, multiple choice survey that should only take 2 minutes to complete.

Thank you,

The MedCity Media Team

Alnylam Pharmaceuticals patents new RNAi therapeutics for hepatitis B infections

3:27 pm by | 0 Comments

RNAiRNAi therapeutics company Alnylam Pharmaceuticals (NasdaqGS:ALNY) disclosed on Thursday the receipt of a US new patent under its McSwiggen patent estate for the advancement of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection.

The company added that the US patent no. 8,618,277, or '277 patent, which includes broad, sequence-independent issued claims on compositions of chemically modified siRNA targeting HBV, was awarded by the US Patent and Trademark Office (USPTO).

According to the company, the McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. The '277 patent includes claims that are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way, concluded the company.



Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Hear the latest news first

Get our daily newsletter or follow us.